BS_4W68NV3M
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 53.88
- os_event
- false
- age_years
- 7.559
- sex
- M
- race
- More Than One Race
- new_clusters
- C3
- umap1_2d
- 5.582655798
- umap2_2d
- 3.787583634
- umap1_3d
- 2.331579325
- umap2_3d
- -1.9449913
- umap3_3d
- -2.541521107
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.220
- WNT_BETA_CATENIN_SIGNALING+0.190
- HEDGEHOG_SIGNALING+0.150
- APICAL_JUNCTION+0.120
- INTERFERON_ALPHA_RESPONSE+0.060
- MYOGENESIS+0.030
- PANCREAS_BETA_CELLS+0.000
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.020
- SPERMATOGENESIS-0.020
- ANGIOGENESIS-0.030
Top 10 suppressed
- MYC_TARGETS_V1-0.670
- OXIDATIVE_PHOSPHORYLATION-0.560
- E2F_TARGETS-0.530
- PROTEIN_SECRETION-0.530
- MTORC1_SIGNALING-0.520
- G2M_CHECKPOINT-0.510
- ANDROGEN_RESPONSE-0.490
- MYC_TARGETS_V2-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-A4SU-01A-11R-A24X-07 | — | cohortA1 | 0.925 |
| 2 | TCGA-CU-A3YL-01A-11R-A22U-07 | — | — | 0.917 |
| 3 | SRR8613808 | — | D | 0.904 |
| 4 | X698ec707.1965.46b2.81ff.3c3445a68d1a | — | cohortA1 | 0.903 |
| 5 | SRR11296732 | — | — | 0.903 |
| 6 | SRR1419714 | GTEX | — | 0.902 |
| 7 | SRR13311169 | — | — | 0.901 |
| 8 | BS_TCGEZJ5F | Supratentorial Ependymoma | — | 0.898 |
| 9 | SRR1797298 | — | cohortSC | 0.897 |
| 10 | MNG441 | — | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.060 | Inavolisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |